167 related articles for article (PubMed ID: 14652981)
1. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
3. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
[TBL] [Abstract][Full Text] [Related]
4. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
Bao H; Lv Y; Wang D; Xue J; Yan Z
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
8. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
Dietrich ES; Schubert B; Ebner W; Daschner F
Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
[No Abstract] [Full Text] [Related]
10. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
Xamplas RC; Itokazu GS; Glowacki RC; Grasso AE; Caquelin C; Schwartz DN
Am J Health Syst Pharm; 2010 Apr; 67(8):622-8. PubMed ID: 20360589
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
13. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.
Duszynska W; Taccone FS; Switala M; Hurkacz M; Kowalska-Krochmal B; Kübler A
Int J Antimicrob Agents; 2012 Feb; 39(2):153-8. PubMed ID: 22154855
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
16. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
Hitt CM; Nightingale CH; Quintiliani R; Nicolau DP
Am J Health Syst Pharm; 1997 Jul; 54(14):1614-8. PubMed ID: 9248605
[TBL] [Abstract][Full Text] [Related]
17. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
[TBL] [Abstract][Full Text] [Related]
20. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]